AbbVie Hits Dr. Reddy's With IP Suit Over Generic Zemplar
Pharmaceuticals maker AbbVie Inc. on Wednesday accused Dr. Reddy's Research Laboratories Ltd. of infringing three drug patents by seeking approval for a generic version of the hyperactive-thyroid medication Zemplar, according to...To view the full article, register now.
Already a subscriber? Click here to view full article